Causation of non-small lung cancer by tyrosine kinase mutation mechanism and its target drug designs and improvements

Abstract

Tyrosine kinase receptor dysregulation is closely associated with diseases such as non-small cell lung cancer (nsclc). Since small molecule inhibitors are able to target the tyrosine kinase receptor and limit its oncogenic activity, the development of targeted drugs has also been a focus of research. This article summarizes the relationship between tyrosine kinase receptors and non-small cell lung cancer, discusses the impact of specific molecular abnormalities in lung cancer on targeted therapies, and the progress of the inhibitor emergency. An integrated approach to treatment will help develop more effective treatment plans for patients that include molecular analysis, targeted therapy, and drug resistance. In addition, the article discusses the impact of personalized care on improving patient health.